<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2633">
  <stage>Registered</stage>
  <submitdate>11/01/2010</submitdate>
  <approvaldate>11/01/2010</approvaldate>
  <nctid>NCT01046422</nctid>
  <trial_identification>
    <studytitle>Safety Study of BMS-770767 in Subjects With Type 2 Diabetes</studytitle>
    <scientifictitle>A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-014308-79</secondaryid>
    <secondaryid>MB117-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-770767
Treatment: drugs - BMS-770767
Treatment: drugs - BMS-770767
Treatment: drugs - BMS-770767
Treatment: drugs - Placebo
Treatment: drugs - Metformin

Experimental: BMS-770767 ± metformin (Treatment A) - 

Experimental: BMS-770767 ± metformin (Treatment B) - 

Experimental: BMS-770767 ± metformin (Treatment C) - 

Experimental: BMS-770767 ± metformin (Treatment D) - 

Placebo Comparator: Placebo ± metformin (Treatment E) - 


Treatment: drugs: BMS-770767
Capsule, Oral, 15mg, Active, Daily, 28 days

Treatment: drugs: BMS-770767
Capsule, Oral, 50mg, Active, Daily, 28 days

Treatment: drugs: BMS-770767
Capsule, Oral, 150mg, Active, Daily, 28 days

Treatment: drugs: BMS-770767
Capsule, Oral, 50mg BID, Active, Daily, 28 days

Treatment: drugs: Placebo
Capsule, Oral, 0mg, Daily, 28 days

Treatment: drugs: Metformin
Tablet, Oral, = 1500mg, Active, Daily, 28 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fasting Plasma Glucose Improvement</outcome>
      <timepoint>Within seven days following dosing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean daily glucose (3-day 7 pt-fingerstick)</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Four (4)-hour post-prandial glucose AUC</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1C</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lipid profiles</outcome>
      <timepoint>Within 28 days following dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosed with type 2 diabetes with inadequate glycemic control and treated with
             either diet and exercise alone, or with stable doses (= 1500mg/d) of metformin for at
             least 8 weeks prior to screening

          -  HbA1c = 7.0% and = 10.0% with FPG = 240mg/dL (13.3 mmol/dL)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Women of childbearing potential

          -  History of diabetic ketoacidosis or hyperosmolar nonketotic coma

          -  Significant cardiovascular history

          -  History of unstable or rapidly progressing renal disease

          -  Impaired renal function defined by a serum creatinine &gt; 1.4mg/dL (124 µmol/L) for
             women and &gt;1.5mg/dL (133 µmol/L) for men

          -  Active liver disease and /or significant abnormal liver function defined as AST &gt; 3X
             ULN and/or ALT &gt; 3XULN and /or serum total bilirubin &gt; 2.0mg/dl</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>76</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Caboolture</hospital>
    <hospital>Local Institution - Meadowbrook</hospital>
    <hospital>Local Institution - Daw Park</hospital>
    <hospital>Local Institution - Geelong</hospital>
    <hospital>Local Institution - Nedlands</hospital>
    <postcode>4510 - Caboolture</postcode>
    <postcode>4131 - Meadowbrook</postcode>
    <postcode>5041 - Daw Park</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Prince Edward Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its
      levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that
      may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01046422</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>